Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia - Trial NCT05645718
Access comprehensive clinical trial information for NCT05645718 through Pure Global AI's free database. This Phase 2 trial is sponsored by M.D. Anderson Cancer Center and is currently Not yet recruiting. The study focuses on Leukemia. Target enrollment is 27 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
M.D. Anderson Cancer Center
Timeline & Enrollment
Phase 2
Apr 30, 2023
Dec 31, 2029
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Summary
To learn if cyclophosphamide, vincristine, and dexamethasone (called mini hyper-CVD) in
 combination with intrathecal (delivered into the spine) chemotherapy (methotrexate,
 hydrocortisone, cytarabine) and compressed rituximab, blinatumomab, and inotuzumab ozogamicin
 (called cRIB) can help to control the disease.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05645718
Non-Device Trial